Sanofi Arixtra longer treatment duration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Synthelabo/Organon's Arixtra (fondaparinux) adds an extended course of treatment for prophylaxis of deep vein thrombosis. FDA cleared the anti-thrombotic agent June 17 for up to 24 days of DVT prophylaxis in patients undergoing hip fracture surgery. Previously, Arixtra was recommended for a five- to nine-day administration perio